EPB41L3 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y2J2 |
---|---|
Clone Names | 100507277 |
Gene ID | 23136 |
---|---|
Other Names | Band 41-like protein 3, 41B, Differentially expressed in adenocarcinoma of the lung protein 1, DAL-1, Band 41-like protein 3, N-terminally processed, EPB41L3, DAL1, KIAA0987 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | EPB41L3 (HGNC:3380) |
---|---|
Function | Tumor suppressor that inhibits cell proliferation and promotes apoptosis. Modulates the activity of protein arginine N- methyltransferases, including PRMT3 and PRMT5. |
Cellular Location | Cytoplasm, cytoskeleton. Cell junction. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm Note=Detected in the cytoplasm of actively dividing cells |
Tissue Location | Expressed at high levels in brain, with lower levels in kidney, intestine, and testis. Detected in lung |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
EPB41L3 is a critical growth regulator in the pathogenesis of meningiomas.
References
Dafou, D., et al. Neoplasia 12(7):579-589(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Hoy, J.L., et al. Mol. Cell. Neurosci. 42(4):466-483(2009)Kang, Q., et al. J. Cell. Sci. 122 (PT 8), 1091-1099 (2009) :Martins-de-Souza, D., et al. Eur Arch Psychiatry Clin Neurosci 259(3):151-163(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.